Abstract 4824
Background
Current standard of care for pts with MIBC who are ineligible for neoadjuvant cis-based chemotherapy is radical cystectomy (RC) + pelvic lymph node dissection (PLND). Due to high rates of recurrence and relatively poor overall survival (OS) with RC + PLND alone, there is an urgent need for novel perioperative systemic therapy regimens. A recent single-arm study (PURE-01; NCT02736266) showed clinical activity of pembrolizumab as single-agent neoadjuvant therapy in pts with MIBC and that high PD-L1 expression was associated with a higher pathologic complete response rate.
Trial design
KEYNOTE-905 (NCT03924895) is a randomized, global, multicenter, phase 3 trial of perioperative pembrolizumab plus RC versus RC alone in cis-ineligible pts with MIBC. Approximately 610 adult (≥18 years) pts with histologically confirmed diagnosis of MIBC (T2-T4aN0M0) with predominant (≥50%) urothelial histology are eligible. Pts must be ineligible to receive cis, have an ECOG PS score of 0-2, and must not have previously received any systemic anticancer therapies for MIBC. Pts will be stratified by clinical T stage (T2 vs T3/4), PD-L1 combined positive score (CPS) (≥10 vs < 10), and geographic region. Pts will be randomly assigned 1:1 to receive either 3 cycles of neoadjuvant pembrolizumab followed by RC + PLND and then 14 cycles of adjuvant pembrolizumab or RC + PLND alone. Pembrolizumab 200 mg will be administered every 3 weeks. CT/MRI imaging will be performed before and after cystectomy. Pts who are disease-free at postcystectomy imaging will continue with serial imaging until progression/discontinuation; all imaging will be assessed by blinded independent central review. Coprimary end points are pathologic complete response (pT0N0) and event-free survival evaluated in pts whose tumors express PD-L1 CPS ≥10 and in all pts irrespective of CPS score. Secondary end points are OS, disease-free survival, and pathologic downstaging. Adverse events (AEs) will be monitored from randomization through 30 days after last dose of study drug (90 days for serious AEs). Patient-reported outcomes will also be measured.
Clinical trial identification
NCT03924895, April 23, 2019.
Editorial acknowledgement
Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA), funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
M. Galsky: Advisory / Consultancy: Janssen, Merck, Astellas, Genentech, BMS, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron, Dracen, Ionvio, NuMab, Dragonfly Therapeutics; Research grant / Funding (institution): Dendreon, Novartis, BMS, Merck, AstraZeneca, Genentech/Roche. A. Necchi: Honoraria (self): Merck, Roche, AstraZeneca, Janssen, Rainier Therapeutics, Bayer, BMS, Clovis; Advisory / Consultancy: Merck, Roche, AstraZeneca, Janssen, Rainier Therapeutics, Bayer, BMS, Clovis; Research grant / Funding (institution): Merck, AstraZeneca; Spouse / Financial dependant: Bayer. N.D. Shore: Advisory / Consultancy: Amgen, Astellas, AstraZeneca, Bayer, BMS, Dendreon, Ferring, Janssen, Merck, MDxHealth, Pfizer, Sanofi, Tolmar; Speaker Bureau / Expert testimony: Astellas, Janssen. F. Witjes: Advisory / Consultancy: Roche, MSD, BMS. K. Nam: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. J.L. Godwin: Full / Part-time employment: Merck & Co., Inc. T.L. Frenkl: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: MSD. E.R. Plimack: Advisory / Consultancy: BMS, Genentech, Incyte, Janssen, Merck; Research grant / Funding (institution): Astellas, BMS, Genentech, Merck, Peloton, Pfizer.
Resources from the same session
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract